List of cosmic entities in Marvel Comics

Numinus Wellness Inc. Reports Q1 2023 Results

Retrieved on: 
Monday, January 16, 2023
G&A, TMS, Mental health, Safety, TSX, KAT, Ketamine, CCR, Growth, Patient, Transcranial magnetic stimulation, Research, Clinical trial, Esketamine, Acquisition, Video game, Pharmaceutical industry, List of cosmic entities in Marvel Comics

VANCOUVER, BC, Jan. 16, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months ended November 30, 2022 ("Q1 2023").

Key Points: 
  • VANCOUVER, BC, Jan. 16, 2023 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months ended November 30, 2022 ("Q1 2023").
  • Gross margin grew to 41.9% during Q1 2023 compared to 6.5% in Q1 2022.
  • At the end of Q1 2023, Numinus had 138 practitioners providing client treatments through its wellness clinics and virtual services, a 13.1% increase from the beginning of the quarter.
  • Q1 2023 gross margin at CCR was 70.9%, an increase of 590 basis points compared to prior quarter.

Numinus to Host Q1 2023 Results Conference Call on January 16, 2023

Retrieved on: 
Wednesday, January 4, 2023
Trauma, Webcast, Anxiety, Depression, TSX, Interest, Pain, Research, Communications satellite, List of cosmic entities in Marvel Comics

Interested parties are invited to participate in the Company's Q1 2023 results conference call and webcast occurring on the same day, at 5:30 p.m. Eastern time / 2:30 p.m. Pacific time.

Key Points: 
  • Interested parties are invited to participate in the Company's Q1 2023 results conference call and webcast occurring on the same day, at 5:30 p.m. Eastern time / 2:30 p.m. Pacific time.
  • During the call, Numinus executives will review the Company's performance and recent initiatives, and answer questions from analysts.
  • To listen to the live webcast, please register at:
    The webcast will also be archived on the Events and Presentations page of Numinus' Investor Relations website: https://www.investors.numinus.com/events-and-presentations
    To participate in the live conference call, please use the following dial-in information:
    Please ask to participate in Numinus' Q1 2023 Results Call.
  • At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

Numinus to Participate in the KCSA Mental Health Virtual Investor Conference on December 15, 2022

Retrieved on: 
Monday, December 12, 2022
The Company, Conference, Research, Pain, Trauma, TSX, Depression, Anxiety, List of cosmic entities in Marvel Comics

This will be a live, interactive online event where investors are invited to ask the company questions in real-time.

Key Points: 
  • This will be a live, interactive online event where investors are invited to ask the company questions in real-time.
  • If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event.
  • For more information about the conference, or to schedule a one-on-one meeting with Numinus' management, please send an email to KCSA Strategic Communications [email protected] .
  • Numinus Wellness (TSX: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies.

Numinus Wellness Inc. Reports Q4 2022 and Annual Results

Retrieved on: 
Tuesday, November 29, 2022
Mental health, Growth, Patent Cooperation Treaty, KAT, United Kingdom, TSX, WIPO, Transcranial magnetic stimulation, Corporation, First Nations in Ontario, CCR, PCT, Patient, United Nations, Fungus, Psilocybe, File, Patent, World Intellectual Property Organization, Ketamine, National Association Medical Staff Services, Research, Psilocybin, TMS, Esketamine, Acquisition, Medicine, Video game, Medical device, Management, Pharmaceutical industry, Health insurance, List of cosmic entities in Marvel Comics

VANCOUVER, BC, Nov. 29, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three and twelve months ended August 31, 2022 ("Q4 2022" and "Fiscal 2022").

Key Points: 
  • VANCOUVER, BC, Nov. 29, 2022 /PRNewswire/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three and twelve months ended August 31, 2022 ("Q4 2022" and "Fiscal 2022").
  • Revenues grew 643% year-over-year to $4.2 million in Q4 2022, due primarily to the acquisition of Novamind.
  • On June 27, 2022, Numinus introduced its new logo and brand identity to unify Numinus' presence across North America.
  • At the end of Q4 2022, Numinus had 122 practitioners providing client treatments through its wellness clinics and virtual services, a 10% increase from the beginning of the quarter.

Numinus to Host Q4 and Year End 2022 Results Conference Call on November 29, 2022

Retrieved on: 
Tuesday, November 15, 2022
Trauma, Anxiety, TSX, Pain, Interest, Forward-looking statement, Depression, Company, Research, Webcast, The Company, Communications satellite, BC, List of cosmic entities in Marvel Comics

Interested parties are invited to participate in the Company's Q4 and year end 2022 results conference call and webcast occurring on the same day, at 5:30 p.m. Eastern time / 2:30 p.m. Pacific time.

Key Points: 
  • Interested parties are invited to participate in the Company's Q4 and year end 2022 results conference call and webcast occurring on the same day, at 5:30 p.m. Eastern time / 2:30 p.m. Pacific time.
  • During the call, Numinus executives will review the Company's performance and recent initiatives, and answer questions from analysts.
  • To listen to the live webcast, please register at: https://events.q4inc.com/attendee/162579419
    The webcast will also be archived on the Events and Presentations page of Numinus' Investor Relations website: https://www.investors.numinus.com/events-and-presentations/default.aspx
    To participate in the live conference call, please use the following dial-in information:
    Please ask to participate in Numinus' Q4 and 2022 Results Call.
  • To avoid any delays in joining the call, please dial in at least five minutes prior to the call start time.

Numinus to Participate in Wonderland: Miami on November 3-5, 2022

Retrieved on: 
Monday, October 31, 2022
Ketamine, TSX, Pain, Research, MD, Forward-looking statement, Microdosing, Depression, Company, Trauma, Anxiety, List of cosmic entities in Marvel Comics, BC

Dr. Reid Robison, MD MBA, Chief Clinical Officer of Numinus, will participate in the panel Neurobiological Mechanism Difference Between Classic Psychedelics and Ketamine on Saturday, November 5th at 9:50 a.m.

Key Points: 
  • Dr. Reid Robison, MD MBA, Chief Clinical Officer of Numinus, will participate in the panel Neurobiological Mechanism Difference Between Classic Psychedelics and Ketamine on Saturday, November 5th at 9:50 a.m.
  • For more information about the conference, or to schedule a one-on-one meeting with Numinus' management, please send an email to KCSA Strategic Communications [email protected] .
  • Numinus Wellness (TSX: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies.
  • At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

Numinus Launches Psychedelic-Assisted Therapy for Chronic and Serious Medical Illness

Retrieved on: 
Friday, October 28, 2022
Ill, Company, Acquisition, Ketamine, MD, VP, Professional, Awareness, Forward-looking statement, Depression, Growth, Chronic pain, Government, Gaps, Policy, Anxiety, Program, Health, Patient, TSX, Public opinion, Industry, Research, COVID-19, Risk, Lists of diseases, Murray, Palliative care, Trauma, Pain, Disease, Perception, Medicine, Pharmaceutical industry, BC, List of cosmic entities in Marvel Comics

"Chronic and serious medical illness encompasses a wide range of diagnoses, from terminal cancer to chronic pain.

Key Points: 
  • "Chronic and serious medical illness encompasses a wide range of diagnoses, from terminal cancer to chronic pain.
  • Numinus' program will offer ketamine-assisted therapy alongside additional community support, and has a targeted focus on improving patients' physical, emotional, mental and spiritual suffering caused by their illness.
  • Care will be provided by health care professionals who are specifically trained in chronic and serious medical illness.
  • "Many patients develop adjustment disorders, including depression and anxiety, as they go through the various stages of chronic and serious medical illness," said Dr. Paul Thielking (MD), Chief Science Officer, Numinus.

Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, October 13, 2022

Retrieved on: 
Friday, October 7, 2022
The Company, TSX, Person, Depression, Research, Company, Acquisition, CEO, Trauma, Pain, Anxiety, Forward-looking statement, BC, List of cosmic entities in Marvel Comics

VANCOUVER, BC, Oct. 7, 2022 /PRNewswire/ - Numinus Wellness Inc.("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO of Numinus, will participate in a Water Tower Research Fireside Chat on Thursday, October 13, 2022, at 2:30 p.m.

Key Points: 
  • VANCOUVER, BC, Oct. 7, 2022 /PRNewswire/ - Numinus Wellness Inc.("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, today announced that Payton Nyquvest, Founder and CEO of Numinus, will participate in a Water Tower Research Fireside Chat on Thursday, October 13, 2022, at 2:30 p.m.
  • The discussion will focus on Numinus' recently completed and transformative acquisition of Novamind; the value this acquisition brings to the Company; and key growth opportunities and catalysts for Numinus.
  • For more information about the conference, or to schedule a one-on-one meeting with Numinus' management, please send an email to KCSA Strategic Communications [email protected] .
  • At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.

Numinus Develops Mushroom Tea for Use in Psychedelic Research

Retrieved on: 
Wednesday, October 5, 2022
Government, Professional, Growth, TSX, Policy, Patient, Perception, Depression, Research, Health Canada, Company, Acquisition, Palliative care, Scientific method, Industry, Market Access Program, Trauma, Pain, Innovation, Anxiety, Forward-looking statement, COVID-19, Public opinion, Health, Risk, Special access program, Pharmaceutical industry, List of cosmic entities in Marvel Comics, Psilocybe

"The Numinus team has developed the Psilocybe tea bag with scientific precision in mind," said Sharan Sidhu, Numinus VP, Scientific Research, Innovation & Laboratory Operations.

Key Points: 
  • "The Numinus team has developed the Psilocybe tea bag with scientific precision in mind," said Sharan Sidhu, Numinus VP, Scientific Research, Innovation & Laboratory Operations.
  • The research behind the tea bag involved the development of processes and procedures to deliver 25mg per dose and the use of Numinus' validated strains of Psilocybe cubensis.
  • The tea bag will be studied in a phase 1 trial of practitioners receiving experiential training for psilocybin-assisted therapy, with the goal to be used in Numinus' research, including trial partnerships at Cedar Clinical Research, Numinus' clinical trial management division.
  • The Numinus model - including psychedelic production, research and clinic care - is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use.

Numinus to Participate in the Cantor Neurology & Psychiatry Conference on October 6-7, 2022

Retrieved on: 
Thursday, September 29, 2022
TSX, The Ritz-Carlton Hotel Company, Company, Thought, Forward-looking statement, Trauma, CEO, Pain, Cantor, Anxiety, Research, Conference, Neuropsychology, Depression, Pharmaceutical industry, Medicine, List of cosmic entities in Marvel Comics, BC

Payton Nyquvest, Founder and CEO of Numinus, will participate in the Digital-Pharma and a New Way of Thinking for NeuroPsych panel on Friday, October 7th at 9:00 a.m. PT.

Key Points: 
  • Payton Nyquvest, Founder and CEO of Numinus, will participate in the Digital-Pharma and a New Way of Thinking for NeuroPsych panel on Friday, October 7th at 9:00 a.m. PT.
  • In addition, Numinus will participate in the Cantor Symposium on Mental Health Clinics on Tuesday, October 11, 2022.
  • Mr. Nyquvest will participate in a virtual fireside chat with Pablo Zuanic, Cantor Research Analyst, at 11:00 a.m.
  • At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.